Bioequivalence Study of Epalrestat for Healthy Chinese Subjects
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1347 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Dandan Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center of Clinical Pharmacology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Area Under Curve, Healthy Volunteers, Rhodanine, Therapeutic Equivalency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Epalrestat is a reversible noncompetitive inhibitor of aldose reductase with selective inhibition of aldose reductase. It can inhibit the accumulation of sorbitol in red blood cells in patients with diabetic peripheral neuropathy and can improve patients’ conscious symptoms and neurological dysfunction. This study was designed to evaluate the bioequivalence in healthy Chinese subjects of a new test formulation and reference formulation of oral epalrestat (50 mg) in the fasting state. The study was performed with 44 healthy Chinese subjects according to a randomized 2‐way crossover design. The main pharmacokinetic parameters of test formulation and reference formulation as follows: 4793 and 4781 ng/mL for maximum plasma concentration, 8556 and 8431 ng h/mL for area under the plasma concentration‐time curve extrapolated to infinity. The test formulation of epalrestat was bioequivalent to the reference formulation. The bioequivalence study of epalrestat in healthy Chinese subjects suggests that the test and reference formulations have similar pharmacokinetics and both formulations are well tolerated in the dose range studied in healthy Chinese subjects. All these findings provided valuable pharmacokinetic knowledge for further clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Clinical Pharmacology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
Zitieren
APA
Yang, D., Wang, X., Duan, Y., Xu, Y., Ruan, Z., Jiang, B., Lou, H., & Chen, J. (2024). Bioequivalence Study of Epalrestat for Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1347
Vancouver
Yang D, Wang X, Duan Y, Xu Y, Ruan Z, Jiang B, et al. Bioequivalence Study of Epalrestat for Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1347
BibTeX
@article{Yang2024,
author = {Yang, Dandan and Wang, Xiaodan and Duan, Yi and Xu, Yichao and Ruan, Zourong and Jiang, Bo and Lou, Honggang and Chen, Jinliang},
title = {Bioequivalence Study of Epalrestat for Healthy Chinese Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1347}
}
EUVIMED